- Industry
- 1 min read
EU Commission to end AstraZeneca and J&J vaccine contracts at expiry - paper
The European Commission, in agreement with the leaders of many (EU) countries, has decided that the contracts with the companies that produce (viral vector) vaccines that are valid for the current year will not be renewed at their expiry.
"The European Commission, in agreement with the leaders of many (EU) countries, has decided that the contracts with the companies that produce (viral vector) vaccines that are valid for the current year will not be renewed at their expiry," the newspaper reported.
It added that Brussels would rather focus on Covid-19 vaccines using messenger RNA (mRNA) technology, such as Pfizer's and Moderna's.
A spokesman for the EU Commission said it was keeping all options open to be prepared for the next stages of the pandemic, for 2022 and beyond.
"We cannot, however, comment on contractual issues," the spokesman added.
The Italian health ministry declined to comment.
The European Commission is seeking clarification from J&J about the company's "completely unexpected" announcement of delays in Covid-19 vaccine deliveries to the EU, an EU official told Reuters on Tuesday.
COMMENTS
All Comments
By commenting, you agree to the Prohibited Content Policy
PostBy commenting, you agree to the Prohibited Content Policy
PostFind this Comment Offensive?
Choose your reason below and click on the submit button. This will alert our moderators to take actions